Enhanced radiation response through directed molecular targeting approaches

Wheldon TE, Mairs RJ, Rampling RP, Barrett A: Modeling the enhancement of fractionated radiotherapy by gene transfer to sensitize tumor cells to radiation. Radiother Oncol, 48: 5–13, 1998 Ma BB, Bristow RG, Kim J, Siu LL: Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol, 21: 2760–2776, 2003 Greco O, Scott SD, Marples B, Dachs GU: Cancer gene therapy: 'Delivery, delivery, delivery'. Front Biosci, 7: d1516–1524, 2002 Burton EA, Bai Q, Goins WF, Glorioso JC: Replication-defective genomic herpes simplex vectors: design and production. Curr Opin Biotechnol, 13: 424–428, 2002 Burton EA, Fink DJ, Glorioso JC: Gene delivery using herpes simplex virus vectors. DNA Cell Biol, 21: 915–936, 2002 Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T, He TC: Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther, 1: 149–162, 2001 Lai CM, Lai YK, Rakoczy PE: Adenovirus and adenoassociated virus vectors. DNA Cell Biol, 21: 895–913, 2002 Vorburger SA, Hunt KK: Adenoviral gene therapy. Oncologist, 7: 46–59, 2002 Quinonez R, Sutton RE: Lentiviral vectors for gene delivery into cells. DNA Cell Biol, 21: 937–951, 2002 Peplinski GR, Tsung K, Norton JA: Vaccinia virus for human gene therapy. Surg Oncol Clin N Am, 7: 575–588, 1998 Hope MJ, Mui B, Ansell S, Ahkong QF: Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Mol Membr Biol, 15: 1–14, 1998 Herweijer H, Wolff JA: Progress and prospects: Naked DNA gene transfer and therapy. Gene Ther, 10: 453–458, 2003 Bogoyevitch MA, Kendrick TS, Ng DC, Barr RK: Taking the cell by stealth or storm? Protein transduction domains (PTDs) as versatile vectors for delivery. DNA Cell Biol, 21: 879–894, 2002 Hudson AJ, Normand N, Ackroyd J, Akhtar S: Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharm, 182: 49–58, 1999 Smyth Templeton N: Liposomal delivery of nucleic acids in vivo. DNA Cell Biol, 21: 857–867, 2002 Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC: Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med, 9: 357–363, 2003 Derossi D, Chassaing G, Prochiantz A: Trojan peptides: The penetratin system for intracellular delivery. Trends Cell Biol, 8: 84–87, 1998 Trezise AE: In vivo DNA electrotransfer. DNA Cell Biol, 21: 869–877, 2002 Collis SJ, Khater K, DeWeese TL: Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol, 21: 275–289, 2003 Lundstrom K: Latest development in viral vectors for gene therapy. Trends Biotechnol, 21: 117–122, 2003 Pierce ML, Ruffner DE: Construction of a directed hammerhead ribozyme library: Towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Res, 26: 5093–5101, 1998 Dash P, Lotan I, Knapp M, Kandel ER, Goelet P: Selective elimination of mRNAs in vivo: Complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci USA, 84: 7896–7900, 1987 Walder RY, Walder JA: Role of RNase H in hybridarrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA, 85: 5011–5015, 1988 Myers KJ, Dean NM: Sensible use of antisense: How to use oligonucleotides as research tools. Trends Pharmacol Sci, 21: 19–23, 2000 Branch AD: Antisense drug discovery: Can cell-free screens speed the process? Antisense Nucleic Acid Drug Dev, 8: 249–254, 1998 Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B: Antisense therapy: Current status in prostate cancer and other malignancies. Cancer Metastasis Rev, 21: 79–92, 2002 Jansen B, Zangemeister-Wittke U: Antisense therapy for cancer—the time of truth. Lancet Oncol, 3: 672–683, 2002 Cech TR: Ribozymes, the first 20 years. Biochem Soc Trans, 30: 1162–1166, 2002 Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, Gerlach W: A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther, 10: 2255–2270, 1999 Sandberg JA, Parker VP, Blanchard KS, Sweedler D, Powell JA, Kachensky A, Bellon L, Usman N, Rossing T, Borden E, Blatt LM: Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol, 40: 1462–1469, 2000 Welch PJ, Barber JR, Wong-Staal F: Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr Opin Biotechnol, 9: 486–496, 1998 Wong-Staal F, Poeschla EM, Looney DJ: A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther, 9: 2407–2425, 1998 Bettinger T, Read ML: Recent developments in RNAbased strategies for cancer gene therapy. Curr Opin Mol Ther, 3: 116–124, 2001 Freelove AC, Zheng R: The power of ribozyme technologies: The logical way ahead for molecular medicine and gene therapy? Curr Opin Mol Ther, 4: 419–422, 2002 Kashani-Sabet M: Ribozyme therapeutics. J Investig Dermatol Symp Proc, 7: 76–78, 2002 Wright L, Kearney P: Current status of ribozymes as gene therapy agents for cancer. Cancer Invest, 19: 495–509, 2001 Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411: 494–498, 2001 Hammond SM, Caudy AA, Hannon GJ: Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet, 2: 110–119, 2001 Hannon GJ: RNA interference. Nature, 418: 244–251, 2002 Zamore PD: RNA interference: Listening to the sound of silence. Nat Struct Biol, 8: 746–750, 2001 Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev, 16: 948–958, 2002 Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet, 32: 107–108, 2002 Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P: Lentiviral-mediated RNA interference. Hum Gene Ther, 13: 2197–2201, 2002 McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA: RNA interference in adult mice. Nature, 418: 38–39, 2002 Shen C, Buck AK, Liu X, Winkler M, Reske SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett, 539: 111–114, 2003 Zhao LJ, Jian H, Zhu H: Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene, 316: 137–141, 2003 Ward JF: DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol, 35: 95–125, 1988 Hoeijmakers, JH: Genome maintenance mechanisms for preventing cancer. Nature, 411: 366–374, 2001 Jackson SP: Detecting, signaling and repairing DNA double-strand breaks. Biochem Soc Trans, 29: 655–661, 2001 Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer, 3: 155–168, 2003 Petrini JH, Stracker TH: The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol, 13: 458–462, 2003 Valerie K, Povirk LF: Regulation and mechanisms of mammalian double-strand break repair. Oncogene, 22: 5792–5812, 2003 Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ: ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis, 24: 1571–1580, 2003 Iliakis G: The role of DNA double strand breaks in ionizing radiation-induced killing of eukaryotic cells. Bioessays, 13: 641–648, 1991 Iliakis G, Wang Y, Guan J, Wang H: DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene, 22: 5834–5847, 2003 Moses RE: DNA damage processing defects and disease. Annu Rev Genomics Hum Genet, 2: 41–68, 2001 Levitt NC, Hickson ID: Caretaker tumor suppressor genes that defend genome integrity. Trends Mol Med, 8: 179–186, 2002 Thompson LH, Schild D: Recombinational DNA repair and human disease. Mutat Res, 509: 49–78, 2002 Shiloh Y: ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev, 11: 71–77, 2001 Yoshida M, Hosoi Y, Miyachi H, Ishii N, Matsumoto Y, Enomoto A, Nakagawa K, Yamada S, Suzuki N, Ono T: Roles of DNA-dependent protein kinase and ATM in cellcycle-dependent radiation sensitivity in human cells. Int J Radiat Biol, 78: 503–512, 2002 Rotman G, Shiloh Y: ATM: from gene to function. Hum Mol Genet, 7: 1555–1563, 1998 van den Bosch M, Bree RT, Lowndes NF: The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep, 4: 844–849,2003 Powell SN, Kachnic LA: Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene, 22: 5784–5791, 2003 Powell SN, Willers H, Xia F: BRCA2 keeps Rad51 in line. High-fidelity homologous recombination prevents breast and ovarian cancer? Mol Cell, 10: 1262–1263, 2002 Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, Yamauchi A, Inamoto T, Ko K, Yazumi S, Motoda H, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R: Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer, 88: 28–36, 2000 Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T: The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer, 105: 472–479, 2003 Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H, Sturzbecher HW: DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene, 19: 2791–2795, 2000 Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, Feller AC, Lopens A, Diedrich K, Schwinger E, Sturzbecher HW: Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer, 88: 907–913, 2000 Sirzen F, Nilsson A, Zhivotovsky B, Lewensohn R: DNA-dependent protein kinase content and activity in lung carcinoma cell lines: correlation with intrinsic radiosensitivity. Eur J Cancer, 35: 111–116, 1999 Zhao HJ, Hosoi Y, Miyachi H, Ishii K, Yoshida M, Nemoto K, Takai Y, Yamada S, Suzuki N, Ono T: DNA-dependent protein kinase activity correlates with Ku70 expression and radiation sensitivity in esophageal cancer cell lines. Clin Cancer Res, 6: 1073–1078, 2000 Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, Hamakawa H: Up-regulation of DNAdependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci, 94: 894–900, 2003 Wilson CR, Davidson SE, Margison GP, Jackson SP, Hendry JH, West CM: Expression of Ku70 correlates with survival in carcinoma of the cervix. Br J Cancer, 83: 1702–1706, 2000 Angele S, Treilleux I, Bremond A, Taniere P, Hall J: Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology, 43: 347–353, 2003 Lieber MR, Ma Y, Pannicke U, Schwarz K: Mechanism and regulation of human non-homologous DNA endjoining. Nat Rev Mol Cell Biol, 4: 712–720, 2003 Zhang N, Chen P, Gatei M, Scott S, Khanna KK, Lavin MF: An anti-sense construct of full-length ATM cDNA imposes a radiosensitive phenotype on normal cells. Oncogene, 17: 811–818, 1998 Uhrhammer N, Fritz E, Boyden L, Meyn MS: Human fibroblasts transfected with an ATM antisense vector respond abnormally to ionizing radiation. Int J Mol Med, 4: 43–47, 1999 Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C: Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Ther, 7: 1307–1314, 2000 Guha C, Guha U, Tribius S, Alfieri A, Casper D, Chakravarty P, Mellado W, Pandita TK, Vikram B: Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors. Gene Ther, 7: 852–858, 2000 Collis SJ, Swartz MJ, Nelson WG, DeWeese TL: Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res, 63: 1550–1554, 2003 Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB: Fragments of ATM which have dominant-negative or complementing activity. Mol Cell Biol, 17: 2020–2029, 1997 Chen S, Paul P, Price BD: ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response. Oncogene, 22: 6332–6339, 2003 Durocher D, Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol, 13: 225–231, 2001 Featherstone C, Jackson SP: DNA-dependent protein kinase gets a break: its role in repairing DNA and maintaining genomic integrity. Br J Cancer, 80: 14–19, 1999 Smith GC, Jackson SP: The DNA-dependent protein kinase. Genes Dev, 13: 916–934, 1999 Jeggo PA, Taccioli GE, Jackson SP: Menage a trois: double strand break repair, V(D)J recombination and DNA-PK. Bioessays, 17: 949–957, 1995 Marangoni E, Le Romancer M, Foray N, Muller C, Douc-Rasy S, Vaganay S, Abdulkarim B, Barrois M, Calsou P, Bernier J, Salles B, Bourhis J: Transfer of Ku86 RNA antisense decreases the radioresistance of human fibroblasts. Cancer Gene Ther, 7: 339–346, 2000 Belenkov AI, Paiement JP, Panasci LC, Monia BP, Chow TY: An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res, 62: 5888–5896, 2002 Li GC, He F, Shao X, Urano M, Shen L, Kim D, Borrelli M, Leibel SA, Gutin PH, Ling CC: Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res, 63: 3268–3274, 2003 Omori S, Takiguchi Y, Suda A, Sugimoto T, Miyazawa H, Tanabe N, Tatsumi K, Kimura H, Pardington PE, Chen F, Chen DJ, Kuriyama T: Suppression of a DNA double-strand break repair gene, Ku70, increases radioand chemosensitivity in a human lung carcinoma cell line. DNA Repair (Amst), 1: 299–310, 2002 Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, Budach V: Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res, 62: 6621–6624, 2002 Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS: Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res, 62: 6400–6404, 2002 Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW: A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity, 9: 367–376, 1998 Li S, Takeda Y, Wragg S, Barrett J, Phillips A, Dynan WS: Modification of the ionizing radiation response in living cells by an scFv against the DNA-dependent protein kinase. Nucleic Acids Res, 31: 5848–5857, 2003 Lees-Miller SP, Long MC, Kilvert MA, Lam V, Rice SA, Spencer CA: Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. J Virol, 70: 7471–7477, 1996 Parkinson J, Lees-Miller SP, Everett RD: Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol, 73: 650–657, 1999 Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL: Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia, 3: 451–456, 2001 Boyer J, Rohleder K, Ketner G: Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology, 263: 307–312, 1999 Collis SJ, Ketner GW, Hicks JL, Nelson WG, Demarzo AM, Deweese TL: Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells. Int J Radiat Biol, 79: 53–60, 2003 Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD: The Mre11 complex is required for ATM activation and the G(2)/M checkpoint. Embo J, 22: 6610–6620, 2003 Stracker TH, Carson CT, Weitzman MD: Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature, 418: 348–352, 2002 Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC: CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res, 61: 5453–5460, 2001 Kim YC, Koh JT, Shin BA, Ahn KY, Choi BK, Kim CG, Kim KK: An antisense construct of full-length human RAD50 cDNA confers sensitivity to ionizing radiation and alkylating agents on human cell lines. Radiat Res, 157: 19–25, 2002 O'Malley BW Jr, Li D, Carney J, Rhee J, Suntharalingam M: Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer. Laryngoscope, 113: 1588–1594, 2003 Xu M, Myerson R, Hunt C, Kumar S, Moros E, Straube B, Roti JR: Treatment of cells with Mre11 siRNA increases radiation sensitivity and reduces heat induced radiosensitization. Int J Radiat Oncol Biol Phys, 57: S144–145, 2003 Goldberg M, Stucki M, Falck J, D'Amours D, Rahman D, Pappin D, Bartek J, Jackson SP: MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature, 421: 952–956, 2003 Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ: Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol, 160: 1017–1027, 2003 Lou Z, Chini CC, Minter-Dykhouse K, Chen J: Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J Biol Chem, 278: 13599–13602, 2003 Lou Z, Minter-Dykhouse K, Wu X, Chen J: MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature, 421: 957–961, 2003 Qi W, Martinez JD: Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res, 160: 217–223, 2003 Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ: MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature, 421: 961–966, 2003 Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, Weichselbaum RR: Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem, 15: 15, 2003 Yu Q, Rose JH, Zhang H, Pommier Y: Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett, 505: 7–12, 2001 Zhao H, Watkins JL, Piwnica-Worms H: Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA, 99: 14795–14800, 2002 Taki T, Ohnishi T, Yamamoto A, Hiraga S, Arita N, Izumoto S, Hayakawa T, Morita T: Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophys Res Commun, 223: 434–438, 1996 Ohnishi T, Taki T, Hiraga S, Arita N, Morita T: In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun, 245: 319–324, 1998 Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP: Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res, 29: 1534–1538, 2001 Watson G, Jensen R: Effect of hRAD51 dominant negative mutant expression in a glioblastoma model system: altered sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys, 57: S145, 2003 Brunner TB, Gupta AK, Shi Y, Hahn SM, Muschel RJ, McKenna WG, Bernhard EJ: Farnesyltransferase inhibitors as radiation sensitizers. Int J Radiat Biol, 79: 569–576, 2003 Kasid U, Dritschilo A: RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene, 22: 5876–5884, 2003 Li Q, Zhu GD: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem, 2: 939–971, 2002 McKenna WG, Muschel RJ: Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer, 38: 330–338, 2003 Shangary S, Johnson DE: Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia, 17: 1470–1481, 2003 Tenzer A, Pruschy M: Potentiation of DNA-damageinduced cytotoxicity by G2 checkpoint abrogators. Curr Med Chem Anti-Canc Agents, 3: 35–46, 2003 Tenzer A, Zingg D, Riesterer O, Vuong V, Bodis S, Pruschy M: Signal transduction inhibitors as radiosensitizers. Curr Med Chem Anti-Canc Agents, 2: 727–742, 2002 Zaffaroni N, Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat, 5: 65–72, 2002 Zhou BB, Anderson HJ, Roberge M: Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther, 2: S16–22, 2003 Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A, Mark GE: Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science, 243: 1354–1356, 1989 Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U: Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev, 9: 191–201, 1999 Moreira JN, Simoes S: Technology evaluation: LErafAON, NeoPharm. Curr Opin Mol Ther, 5: 547–552, 2003 Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res, 8: 3276–3284, 2002 Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME: Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumor model. BJU Int, 92: 463–469, 2003 Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res, 91: 1204–1209, 2000 Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N: A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res, 93: 1057–1062, 2002 Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys, 55: 1341–1347, 2003 Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer, 86: 886–892, 2002 Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone MG, Zaffaroni N: Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol, 120: 648–654, 2003 Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, Gumerlock PH: BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm, 17: 647–656, 2002 Greenberger JS, Epperly MW, Gretton J, Jefferson M, Nie S, Bernarding M, Kagan V, Guo HL: Radioprotective gene therapy. Curr Gene Ther, 3: 183–195, 2003 Kuninaka S, Ichinose Y, Koja K, Toh Y: Suppression of manganese superoxide dismutase augments sensitivity to radiation, hyperthermia and doxorubicin in colon cancer cell lines by inducing apoptosis. Br J Cancer, 83: 928–934, 2000 Ueta E, Yoneda K, Kimura T, Tatemoto Y, Doi S, Yamamoto T, Osaki T: Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21. Int J Cancer, 94: 545–550, 2001 Choy H, Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst, 95: 1440–1452, 2003 Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S: COX-2-dependent stabilization of survivin in non-small cell lung cancer. Faseb J, 3: 3, 2003